Summary
In the prior quarter, Revenue expanded on contribution from the INVASE buy/sell model, while earnings swung to a loss due to gross-up and upfront investment. Mogecheck slowed amid financial institutions’ tighter marketing spend and changes to monetization points, but KPIs continued to trend up. Key 2Q debates are (i) demand-generation initiatives and early benefits from partnerships, (ii) continued improvement in INVASE profitability, and (iii) absorption of the revenue recognition timing lag at Mogecheck. Over the medium term, differentiation is underpinned by credit analysis capabilities and data assets; the key question is whether the Company can shift its focus from growth “quantity” to growth “quality” (gross profit and ROIC).
Key Points To Watch Next Quarter
| Key Points & Focus | Implications |
|---|---|
Revenue GrowthINVASE buy/sell model: purchase/sale transaction volume and ASP (1Q Revenue JPY 1,095M) | If growth continues with gross profit support, there is upside to progress versus the full-year Revenue plan of JPY 3,779M. |
ProfitabilityRebound in consolidated gross margin (31.4% in 1Q) and improvement in INVASE segment P&L (1Q loss in the JPY 4M range) | Confirmation of gross margin improvement would signal entry into a profit-generation phase, providing a read-through to the timing of a return to operating profitability. |
Strategy ExecutionPenetration of Mogecheck “Pre-Screening” and impact from the shift to execution-based monetization | If shrinking revenue recognition lag and stable CPA are confirmed, confidence in a 2H recovery scenario increases. |
Financial HealthUse of long-term borrowings and inventory (property held for sale) turnover (1Q inventory JPY 247M, borrowings JPY 391M) | Faster inventory turns and stable net D/E are prerequisites for improved capital efficiency (ROIC>WACC). |
Customers / KPIsMogecheck traffic 1,776K (+37.2%), registrations 30,469 (+37.1%), INVASE contracts 116 (+61.1%) | Leading indicators for the top line. Assess growth quality by checking KPI quality (CVR, ARPU). |
Capital PolicyExecution progress of the capital and business alliance and dilution impact | If alliance synergies translate into higher gross profit / deal sourcing, shareholder value creation can outweigh dilution. |
Regulation / Market EnvironmentInterest-rate trends and shifts in fixed vs. floating preference | Mogecheck’s recovery hinges on adaptability in product design and go-to-market strategy amid rising rates. |
Key Debates From The Prior Results (FY2026 1Q)
The prior quarter delivered Revenue of JPY 1,405M (+163.5% YoY) but an operating loss of JPY 11M. The revenue mix shifted due to contribution from the INVASE buy/sell model, pressuring gross margin. The Company continues upfront investment in marketing and generative AI development to maximize medium-to-long-term earnings power.
1. Segment Mix Shift And Gross Margin Quality
- Prior quarter: Mogecheck Revenue JPY 310M, INVASE Revenue JPY 1,095M. Gross Profit JPY 441M, gross margin 31.4%.
- What to confirm this quarter: Sustainability of ASP and gross margin under the INVASE buy/sell model; recovery in the mix of higher value-added deals at Mogecheck.
- Metrics to watch: Segment gross margins, gross profit per INVASE transaction, quarterly trend in Mogecheck close rate/ARPU.
2. Mogecheck Revenue Recognition Change And KPI Growth
- Prior quarter: Shift to execution-based monetization pushed revenue recognition back by 3–6 months. Traffic 1,776,095 (+37.2%), registrations 30,469 (+37.1%).
- What to confirm this quarter: Shortening of the recognition lag and improvement in LTV/CAC; CVR uplift from the pre-screening feature.
- Metrics to watch: Executed loan volumes, CVR, CPA, LTV/CAC, share via pre-screening.
3. INVASE Profitability Improvement And Scaling
- Prior quarter: 116 contracts (+61.1%), segment loss JPY 4M. Improved profitability as the business shifted from brokerage to a buy/sell-centered model.
- What to confirm this quarter: Purchase-to-sale cycle days and inventory quality, sustainability of monthly profitability, ramp-up in rental property management.
- Metrics to watch: Inventory turnover days, gross profit per transaction, rental management stock (units), repeatable sourcing rate.
4. Cost Structure And Payback From Upfront Investment
- Prior quarter: SG&A JPY 453M; near-term profitability was pressured by upfront investment in generative AI-enabled development and marketing.
- What to confirm this quarter: Marketing ROI improvement; quantification of operating efficiency gains and CVR uplift from AI deployment.
- Metrics to watch: SG&A ratio, marketing ROI, product metrics (funnel conversion: sessions → applications → execution).
5. Balance Sheet Shift And Capital Efficiency
- Prior quarter: Total Assets JPY 2,868M (+JPY 330M), long-term borrowings of JPY 391M recorded, Equity Ratio 77.9% (vs. 87.7% at prior FY-end).
- What to confirm this quarter: Turn management of borrowings and cash generation from inventory sales; confidence in ROIC>WACC.
- Metrics to watch: Operating CF, inventory turns, net D/E, ROIC (this report’s estimates are assessed within the scope of disclosed figures).
Major Timely Disclosures This Fiscal Year
- 2025/11/20Announced a capital and business alliance with Zenkyoren Guarantee Co., Ltd. and issuance of new shares through third-party allotment, etc. - The alliance, including a 10% equity stake, aims to expand Mogecheck by leveraging data and partner networks in the mortgage domain. Near-term earnings impact is limited, but positive for medium-term gross profit and deal sourcing. Notice Regarding Capital and Business Alliance with Zenkyoren Guarantee, etc. (PDF) f.irbank.net
- 2025/11/20FY2026 1Q earnings briefing transcript - Explained Mogecheck’s revenue recognition lag and the outlook for INVASE turning profitable. Presented three strategic pillars (special interest rates, real-time screening, generative AI). Earnings Briefing Transcript (PDF) f.irbank.net
- 2025/11/13Revision to FY2026 full-year guidance - Upgraded Revenue guidance from JPY 2,640M to JPY 3,779M, while keeping the profit plan unchanged. Reflects growth in the INVASE buy/sell model. Revision to Full-Year Guidance (PDF) f.irbank.net
- 2025/11/13Purchases by officers and employees under the share purchase program - Planned for 20 trading days starting the business day after the next earnings announcement, with an upper limit of JPY 54.10M. Aims to improve motivation and align with shareholder value. Regarding Officers’ and Employees’ Purchases of Treasury Shares (PDF) f.irbank.net
Prior Quarter Results (FY2026 1Q Actuals)
The Company operates Mogecheck, which provides mortgage comparison and underwriting estimates, and INVASE, a real estate investment platform. In 1Q, revenue was driven by expansion of INVASE’s buy/sell model, while operating profit remained in the red due to gross-up and upfront investment. KPIs that form the foundation of the mid-term plan continued to grow, with proprietary data and algorithms as key differentiators.
| Item | Amount (JPY M) | YoY | Versus Company Plan | Notes |
|---|---|---|---|---|
| Revenue | 1,405 | +163.5% | - | Contribution from INVASE buy/sell model; gross-up impact |
| Operating Income | -11 | ― | - | Gross margin 31.4%; continued upfront investment |
| Recurring Profit | -7 | ― | - | Non-operating income/expense was immaterial |
| Net Income | -16 | ― | - | Loss expanded due to tax posting |
| EPS | -1.84 yen | ― | - | - |
[Progress Versus Full-Year Plan: 37.2% (prior-year period: N/A)]
Company Information
- Company Name: MFS,Inc.
- Ticker: 196A
- Listing Venue: Tokyo Stock Exchange (as stated in the earnings release: TSE)
- Fiscal Year-End: June
- Next Earnings Release (Expected): TBD (not disclosed as of the earnings release)
- Core Businesses: Mogecheck (mortgage recommendations/underwriting estimates, etc.) and INVASE (real estate investment platform, buying/selling, rental management, etc.)
Envalith, Inc. ("Envalith") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and Envalith and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. Envalith has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by Envalith using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, Envalith and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. Envalith and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
Envalith and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
Envalith may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that Envalith is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to Envalith. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of Envalith is strictly prohibited.
- Use for Other Investment Products
Except where Envalith has provided prior written approval, the use of this report and the trademarks or trade names of Envalith or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.